-
UBS Downgrades Novartis To Neutral, Sees 'No Meaningful Earnings Growth Expected Before '18'
Friday, April 1, 2016 - 9:30am | 250Concerns loom over the prospects of Novartis AG (ADR) (NYSE: NVS), with lack of visibility into Alcon and Entresto. UBS’ Alexandra Hauber downgraded the rating for the company from Buy to Neutral, while reducing the price target from CHF100 to CHF72. Analyst Alexandra Hauber pointed out...
-
Amgen, AstraZeneca End Development Pact; Shares Sink
Tuesday, May 26, 2015 - 8:56pm | 331Amgen, Inc. (NASDAQ: AMGN) shares lost about 2.8 percent Tuesday on fallout from the termination of a three-year-old development pact with AstraZeneca plc (NYSE: AZN). Amgen closed at $159.02, off $4.57; AstraZeneca declined 2.5 percent to $67.68. Amgen said late Friday that it would end a co...